Elecsys^® Calcitonin

Thyroid carcinoma is the most common malignancy of the endocrine system. In 5 up to 10% of all thyroid carcinoma patients, a medullary thyroid carcinoma (MTC) is identified.¹ These carcinomas produce elevated serum concentrations of calcitonin and, therefore, can be diagnosed with an exceptional degree of accuracy and specificity by immunoassays measuring serum calcitonin.^2,3

The diagnostic marker calcitonin is a sen­sitive and specific tumor marker for the ­diagnosis, as well as for the life-long monitoring of MTC patients after thyroid surgery.^2,3

A marker with high specificity for MTC (Figure 1)

• Sensitive tool for diagnosis and follow-up of MTC
  
• High correlation with tumor burden, ­supporting early detection of new or ­residual disease²
  

Elecsys^® Calcitonin with high precision

• High sensitivity and precision at low end concentrations ensure improved ­follow-up and monitoring (figure 2)
• High precision across the entire ­measuring range support accurate results⁴

Workflow efficiency with the most complete automated thyroid portfolio

• All tests required for differential diagnosis of thyroid diseases are consolidated on one platform, including routine thyroid ­assays and specialties such as Elecsys TgII, Elecsys Calcitonin, Elecsys Anti-Tg, Elecsys Anti-TPO and Elecsys Anti-TSHR.

Figure 1: Calcitonin is a highly specific marker for MTC, allowing early and specific diagnosis and reliable monitoring. Source: Performance Evaluation Study 2013, data available upon request.

Figure 2: Comparison of interassay CVs (coefficient of variation) at the lowest concentrations tested. Source: package inserts; March 2013.